Many individuals misusing opioids do not enter into treatment. The question of who enters into treatment for their opioid abuse and under what circumstances is complex and shaped by multiple factors. The objective of the current study is to explore the risk factors for wide-ranging and numerous barriers to treatment among social media users.
Method
Opioid-related forums within a popular social media platform were used to recruit non-treatment engaged individuals (≥15 years) who had misused opioids in the past month (n = 144; 66% male; median age 28). Four treatment barrier factors were identified utilizing principle component analysis: (1) stigma, (2) awareness, (3) attitudinal, and (4) denial. A structural equation model (SEM) was then created to explore the risk factors for different types of barriers to OUD treatment.
Results
The most common barriers among participants not engaged in treatment for their opioid misuse were the belief that one should be able to help themselves with their condition (66%), treatment was too expensive (63%), and worries about being labeled or judged (57%). Additionally, SEM results demonstrate stigma barriers, awareness, and attitudinal barriers were associated with mental health comorbidities, opioid abuse and dependence severity, and treatment history. Denial barriers, however, were only associated with treatment history, and structural/financial barriers were only associated with opioid abuse and dependence severity.
Conclusions
Our research findings are relevant for underscoring the wide-ranging and numerous barriers to treatment faced by individuals misusing opioids that are especially concentrated among those who also struggle with comorbid mental illness.
CarlsonRG, NahhasRW, MartinsSS, DaniulaityteR.Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 2016;160:127–134.
6.
MuhuriPK, GfroererJC, DaviesMC.Associations of nonmedical pain reliever use and initiation of heroin use in the United States. Center for Behavioral Health Statistics and Quality, Data Review; 2013. 1–17. http://www.thblack.com/links/rsd/SAMHSA_Aug2013_HeroinUse.pdf.
7.
WuL-T, ZhuH, SwartzMS.Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
8.
ConneryHS.Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
9.
VolkowND, FriedenTR, HydePS, ChaSS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
10.
ProG, GianoZ, CamplainR, . The role of state medicaid expansions in integrating comprehensive mental health services into opioid treatment programs: differences across the rural/urban continuum. Community Ment Health J. 2020:1–6.
11.
KilukBD, YipSW, DeVitoEE, CarrollKM, SofuogluM.Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder. Clin Psychol Sci. 2019;7(6):1190–1206.
12.
FriesenEL, KurdyakP.The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug Alcohol Depend. 2020;216:108244.
13.
el-GuebalyN.Concurrent substance-related disorders and mental illness: the North American experience. World Psychiatry. 2004;3(3):182–187.
14.
NIDA. Common Comorbidities with Substance Use Disorders. National Institute on Drug Abuse; 2018.
15.
BarryDT, CutterCJ, BeitelM, KernsRD, LiongC, SchottenfeldRS.Psychiatric disorders among patients seeking treatment for co-occurring chronic pain and opioid use disorder. J Clin Psychiatry. 2016;77(10):1413–1419.
16.
ShenY, Lo-CiganicW-H, SegalR, GoodinAJ.Prevalence of substance use disorder and psychiatric comorbidity burden among pregnant women with opioid use disorder in a large administrative database. Journal of Psychosomatic Obstetrics & Gynecology. 2009;2020(2014):1–7.
17.
RosicT, NajiL, BaworM, . The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. NDT. 2017;13:1399–1408.
18.
BoscarinoJA, RukstalisM, HoffmanSN, . Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction. 2010;105(10):1776–1782.
19.
AkdağEM, KotanVO, KoseS, . The relationship between internalized stigma and treatment motivation, perceived social support, depression and anxiety levels in opioid use disorder. Psychiat Clin Psych. 2018;28(4):394–401.
20.
GhabrashMF, BahremandA, VeilleuxM, . Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review. J Dual Diagn. 2020;16(2):191–207.
21.
VestNA, McPhersonS, BurnsGL, TragesserS.Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: a finite mixture model. Drug Alcohol Depend. 2020; 209:107940.
22.
WebsterLR.Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741–1748.
23.
GrantBF, StinsonFS, DawsonDA, . Prevalence and co-occurrence of substance use disorders and independentmood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–816.
24.
ShaghaghiA, BhopalRS, SheikhA.Approaches to recruiting 'hard-to-reach’ populations into re-search: a review of the literature. Health Promot Perspect. 2011;1(2):86–94.
25.
ScorsoneKL, HaozousEA, HayesL, CoxKJ.Overcoming barriers: individual experiences obtaining medication-assisted treatment for opioid use disorder. Qual Health Res. 2020;30(13):2103–2117.
26.
PatrickSW, BuntinMB, MartinPR, . Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states. Substance Abuse. 2019;40(3):356–362.
27.
TofighiB, WilliamsAR, ChemiC, Suhail-SindhuS, DicksonV, LeeJD.Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409–2419.
28.
StumboSP, YarboroughBJH, McCartyD, WeisnerC, GreenCA.Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. J Subst Abuse Treat. 2017;73:47–54.
29.
LeinerDJ. Too fast, too straight, too weird: Post hoc identification of meaningless data in internet surveys. In Survey Research Methods. 2013;13(3):229–248.
30.
FittsWH, WarrenWL.Tennessee Self-Concept Scale, TSCS 2 Manual. 2nd ed. Los Angeles, CA: Western Psychological Services; 1996.
31.
FittsWH, WarrenWL.Tennessee Self-Concept Scale, TSCS-2 Manual. 2nd ed. Los Angeles, CA: Western Psychological Services; 1997.
32.
CachelinFM, Striegel-MooreRH.Help seeking and barriers to treatment in a community sample of Mexican American and European American women with eating disorders. Int J Eat Disord. 2006;39(2):154–161.
33.
KroenkeK, SpitzerRL, WilliamsJB.The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
34.
DelgadilloJ, PayneS, GilbodyS, . How reliable is depression screening in alcohol and drug users? A validation of brief and ultra-brief questionnaires. J Affect Disord. 2011;134(1–3):266–271.
35.
SpitzerRL, KroenkeK, WilliamsJW, LöweB.A brief measure for assessing generalized anxiety disorder: The gad-7. Arch Intern Med. 2006;166(10):1092–1097.
36.
KroenkeK, SpitzerRL, WilliamsJW, MonahanPO, LöweB.Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–325.
37.
DelgadilloJ, PayneS, GilbodyS, . Brief case finding tools for anxiety disorders: validation of GAD-7 and GAD-2 in addictions treatment. Drug Alcohol Depend. 2012;125(1–2):37–42.
38.
WickershamJA, AzarMM, CannonCM, AlticeFL, SpringerSA.Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.
39.
SkinnerHA.The drug abuse screening test. Addict Behav. 1982;7(4):363–371.
40.
GirdenE.Evaluating Research Articles: From Start to Finish. 2nd ed. Thousand Oaks, CA; London: Sage; 2011.
41.
WakemanSE, RichJD.Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.
42.
HilarioEY, GriffinML, McHughRK, . Denial of urinalysis-confirmed opioid use in prescription opioid dependence. J Subst Abuse Treat. 2015;48(1):85–90.
43.
StöverH.Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44–54.
44.
PickardH.Denial in addiction. Mind Lang. 2016;31(3):277–299.
45.
WuL-T, BlazerDG, LiT-K, WoodyGE.Treatment use and barriers among adolescents with prescription opioid use disorders. Addict Behav. 2011;36(12):1233–1239.
SatorraA, BentlerPM.Corrections to test statistics and standard errors in covariance structure analysis. Latent Variables Analysis: Applications for Developmental Research. Thousand Oaks, CA, US: Sage Publications, Inc; 1994. p. 399–419.
48.
SatorraA, BentlerP.Scaling Corrections for Statistics in Covariance Structure Analysis. UCLA; 1988.
49.
HuL-t, BentlerPM.Fit indices in covariance structure modeling: Sensitivity to underparameterized model misspecification. Psychological Methods. 1998;3(4):424–453.
50.
MuthenL, MuthenB.Mplus User's Guide Sixth Edition ed. Loc Angeles, CA: Muthen & Muthen; 1998. p. 2017.
51.
StataCorp. Stata SE Statistical Software: Version 15. College Station, TX: StataCorp LP; 2017.
52.
FederKA, MojtabaiR, MusciRJ, LetourneauEJ.U.S. adults with opioid use disorder living with children: treatment use and barriers to care. Journal of Substance Abuse Treatment. 2018;93:31–37.
53.
ForbesMK, CromeE, SunderlandM, WuthrichVM.Perceived needs for mental health care and barriers to treatment across age groups. Aging Ment Health. 2017;21(10):1072–1078.
54.
HadlandSE, ParkTW, BagleySM.Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018;13(1):15.
55.
AndradeLH, AlonsoJ, MneimnehZ, . Barriers to mental health treatment: results from the WHO World Mental Health surveys. Psychol Med. 2014;44(6):1303–1317.
56.
CummingC, TroeungL, YoungJT, KeltyE, PreenDB.Barriers to accessing methamphetamine treatment: a systematic review and meta-analysis. Drug Alcohol Depend. 2016;168:263–273.
57.
GatesP, CopelandJ.Chapter 105 - barriers to treatment seeking for cannabis dependence. In: PreedyVR, ed. Handbook of Cannabis and Related Pathologies. San Diego, CA: Academic Press; 2017:1025–1029.
58.
SchulerMS, PuttaiahS, MojtabaiR, CrumRM.Perceived barriers to treatment for alcohol problems: a latent class analysis. Psychiatr Serv. 2015;66(11):1221–1228.
59.
MakWWS, PoonCYM, PunLYK, CheungSF.Meta-analysis of stigma and mental health. Social Science & Medicine. 2007;65(2):245–261.
60.
CorriganPW.Mental health stigma as social attribution: implications for research methods and attitude change. Clinical Psychology: Science and Practice. 2006;7(1):48–67.
61.
SalonerB, SharfsteinJ.A stronger treatment system for opioid use disorders. JAMA. 2016;315(20):2165–2166.
62.
McLellanAT, CariseD, KleberHD.Can the national addiction treatment infrastructure support the public's demand for quality care?Journal of Substance Abuse Treatment. 2003;25(2):117–121.
63.
McLellanAT, MeyersK.Contemporary addiction treatment: a review of systems problems for adults and adolescents. Biol Psychiatry. 2004;56(10):764–770.
64.
KellyTM, DaleyDC.Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(3–4):388–406.
65.
WüsthoffLE, WaalH, GråweRW. The effectiveness of integrated treatment in patients with substance use disorders co-occurring with anxiety and/or depression-a group randomized trial. BMC Psychiatry. 2014;14(1):67.
66.
DrakeRE, EssockSM, ShanerA, . Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv. 2001;52(4):469–476.
67.
PufferS, TorgersonD, WatsonJ.Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ. 2003;327(7418):785–789.
68.
GormanJR, RobertsSC, DominickSA, MalcarneVL, DietzAC, SuHI.A diversified recruitment approach incorporating social media leads to research participation among young adult-aged female cancer survivors. J Adolesc Young Adult Oncol. 2014;3(2):59–65.
69.
KobayashiY, BoudreaultP, HillK, SinsheimerJS, PalmerCG.Using a social marketing framework to evaluate recruitment of a prospective study of genetic counseling and testing for the deaf community. BMC Med Res Methodol. 2013;13:145.
70.
MartinezO, WuE, ShultzAZ, . Still a hard-to-reach population? Using social media to recruit Latino gay couples for an HIV intervention adaptation study. J Med Internet Res. 2014;16(4):e113.
71.
MojtabaiR, ChenL-Y, KaufmannCN, CrumRM.Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders. J Subst Abuse Treat. 2014;46(2):268–273.
72.
BoganC, JenningsL, HaynesL, . Implementation of emergency department–initiated buprenorphine for opioid use disorder in a rural southern state. Journal of Substance Abuse Treatment. 2020;112:73–78.
73.
SevalN, EatonE, SpringerSA.Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases. Open Forum Infect Dis. 2020;73:1–6.
74.
BabuKM, BrentJ, JuurlinkDN.Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246–2255.
